ALLO
Allogene Therapeutics Inc

3,212
Loading...
Loading...
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
229

Frequently Asked Questions

What is Market Cap of Allogene Therapeutics Inc?
What is the 52-week high for Allogene Therapeutics Inc?
What is the 52-week low for Allogene Therapeutics Inc?
What is Allogene Therapeutics Inc stock price today?
What was Allogene Therapeutics Inc stock price yesterday?
What is the PE ratio of Allogene Therapeutics Inc?
What is the Price-to-Book ratio of Allogene Therapeutics Inc?
What is the 50-day moving average of Allogene Therapeutics Inc?
How many employess does Allogene Therapeutics Inc has?

Latest ALLO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.